Shots:
- Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders, focused on TNNI3-associated HCM & ARVC
- The acquisition will complement and bolster LEXEO’s advanced pre-clinical gene therapy pipeline with the addition of three novel programs for rare cardiac diseases
- Additionally, preclinical results from the TNNI3-associated HCM gene therapy program showed compelling expression of the human TNNI3 gene in the heart in mouse models & two ARVC gene therapy programs demonstrated delivery of the gene that codes for Cx43 & PKP2
Click here to read full press release/ article | Ref: Globe Newswire | Image: Yahoo Finance
The post Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for Rare Cardiovascular Diseases first appeared on PharmaShots.
